Biosimilar Contract Manufacturing Market Size, Share, Growth, and Industry Analysis, By Types (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins, ), By Applications (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others, ) , and Regional Insights and Forecast to 2035

Biosimilar Contract Manufacturing Market Size

Global Biosimilar Contract Manufacturing Market size was USD 14.39 billion in 2025 and is projected to reach USD 18.85 billion in 2026 and USD 24.71 billion in 2027, further expanding to USD 214.8 billion by 2035, showing a strong growth rate of 31.04% during the forecast period. Around 65% of pharmaceutical companies are shifting toward outsourcing, while nearly 58% of biologics production depends on contract manufacturers. About 62% of firms are increasing production capacity, and nearly 55% are adopting advanced technologies to improve efficiency and output quality in the Biosimilar Contract Manufacturing Market.

The US Biosimilar Contract Manufacturing Market is also showing strong expansion due to increasing biologics demand and outsourcing trends. Around 68% of pharmaceutical companies in the US rely on contract manufacturing for biosimilars. Nearly 60% of production facilities are upgrading to advanced systems, while about 57% of healthcare providers support biosimilar adoption. In addition, approximately 52% of companies are investing in research and development to improve product quality. Around 55% of biosimilar approvals and production activities are concentrated in the US, making it a key growth region.

Key Findings

• Market Size: $ 14.39 billion (2025) $ 18.85 billion (2026) $ 214.8 billion (2035) 31.04 % showing strong expansion and future growth potential globally.
• Growth Drivers: 72% demand increase, 65% outsourcing adoption, 58% biologics reliance, 60% healthcare support, 55% production expansion, 50% innovation focus.
• Trends: 62% capacity expansion, 57% technology adoption, 55% automation use, 50% digital integration, 48% global expansion, 45% efficiency improvement.
• Key Players: Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific Inc. & more.
• Regional Insights: North America 35%, Europe 30%, Asia-Pacific 25%, Middle East & Africa 10%, driven by outsourcing, healthcare demand, and production expansion.
• Challenges: 63% complexity in production, 58% regulatory pressure, 55% cost burden, 50% quality control issues, 48% delays, 45% skilled workforce shortage.
• Industry Impact: 68% outsourcing growth, 60% efficiency improvement, 58% cost reduction, 55% faster production, 52% innovation increase, 50% global expansion.
• Recent Developments: 60% facility expansion, 58% partnerships growth, 55% automation adoption, 52% market expansion, 50% process improvement, 48% innovation focus.

The Biosimilar Contract Manufacturing Market is highly driven by innovation, efficiency, and global demand for biologics. Around 64% of companies are focusing on improving production processes, while nearly 59% are investing in advanced manufacturing systems. Approximately 56% of firms are expanding into emerging markets to reduce costs and increase accessibility. In addition, about 53% of contract manufacturers are enhancing quality standards to meet regulatory requirements. Nearly 50% of companies are forming strategic partnerships to strengthen production capacity and global reach, supporting long-term market development.

Biosimilar Contract Manufacturing Market Trends

The Biosimilar Contract Manufacturing Market is growing fast as companies look for cost-efficient and scalable production solutions. Around 65% of pharmaceutical companies now prefer outsourcing biosimilar manufacturing to reduce operational burden and improve flexibility. Nearly 58% of biologics developers rely on contract manufacturing organizations to speed up product development timelines. In addition, more than 70% of biosimilar pipelines are supported by third-party manufacturing services, showing strong dependency on outsourcing partners. The demand for monoclonal antibody biosimilars contributes to over 60% of manufacturing activities, making it a key segment in the Biosimilar Contract Manufacturing Market.

Single-use technologies are adopted by approximately 55% of contract manufacturers, improving efficiency and reducing contamination risks. Around 62% of manufacturers have expanded their production capacities to meet rising demand, while 48% are investing in advanced bioprocessing technologies. Furthermore, more than 50% of companies are focusing on emerging markets where biosimilar adoption is increasing rapidly. Regulatory approvals for biosimilars have increased by nearly 40%, boosting contract manufacturing demand. Digitalization and automation are used by about 45% of service providers to enhance production quality. These trends clearly show that the Biosimilar Contract Manufacturing Market is becoming more competitive, technology-driven, and outsourcing-focused.

Biosimilar Contract Manufacturing Market Dynamics

OPPORTUNITY

"Expansion in emerging biosimilar markets"

Emerging economies are creating strong growth opportunities in the Biosimilar Contract Manufacturing Market. Around 68% of healthcare systems in developing regions are increasing their focus on affordable biologic treatments. Nearly 57% of biosimilar manufacturers are entering new markets to expand their reach. Government support for biosimilars has increased by approximately 52%, encouraging more outsourcing partnerships. Additionally, about 49% of contract manufacturers are setting up facilities in low-cost regions to reduce production expenses. The rising patient population and increased healthcare access contribute to nearly 60% growth in biosimilar demand in these regions, making them a key opportunity area.

DRIVERS

"Rising demand for cost-effective biologics"

The need for affordable treatment options is a major driver in the Biosimilar Contract Manufacturing Market. Nearly 72% of patients prefer lower-cost biosimilars compared to branded biologics. Around 66% of healthcare providers are recommending biosimilars due to their cost benefits. Patent expirations of biologics account for about 58% of new biosimilar developments, increasing manufacturing demand. In addition, approximately 61% of pharmaceutical companies are focusing on biosimilars to improve market competition. Outsourcing production helps reduce costs by nearly 45%, making contract manufacturing an attractive option for many companies.

RESTRAINTS

"Complex manufacturing processes"

The Biosimilar Contract Manufacturing Market faces challenges due to complex production requirements. Around 63% of biosimilar manufacturing processes require advanced technology and skilled professionals. Nearly 55% of companies face difficulties in maintaining consistency and quality during large-scale production. Regulatory compliance adds to complexity, with about 50% of manufacturers reporting delays due to strict approval processes. Additionally, approximately 47% of firms struggle with high validation requirements, which slows down production timelines. These complexities limit the entry of small players and increase dependence on experienced contract manufacturers.

CHALLENGE

"High operational and compliance pressure"

Maintaining regulatory standards and operational efficiency is a major challenge in the Biosimilar Contract Manufacturing Market. Around 59% of contract manufacturers face pressure to meet strict global regulatory requirements. Nearly 53% report increased costs due to compliance and quality assurance measures. In addition, about 48% of companies experience delays in approvals due to changing guidelines. Workforce training and skill gaps affect nearly 46% of manufacturing operations. Furthermore, about 51% of firms invest heavily in quality systems to avoid production risks. These challenges impact overall efficiency and slow down market growth despite strong demand.

Segmentation Analysis

The Biosimilar Contract Manufacturing Market is segmented based on type and application, with strong demand across multiple biologic categories. The market value reached USD 14.39 Billion in 2025 and continues to expand with rapid adoption of outsourcing services. Around 60% of manufacturing demand comes from recombinant protein-based biosimilars, showing strong reliance on advanced biologic production. Applications such as oncology and autoimmune disorders together contribute nearly 55% of the total demand, driven by high patient needs and treatment access. Approximately 48% of pharmaceutical companies prefer contract manufacturing for complex biologics due to lower cost and faster production timelines. The segmentation shows clear growth in both type and application areas, with increasing focus on innovation, efficiency, and large-scale production capabilities in the Biosimilar Contract Manufacturing Market.

By Type

Recombinant Non-glycosylated Proteins

Recombinant non-glycosylated proteins account for nearly 42% of the Biosimilar Contract Manufacturing Market due to their simpler structure and easier production process. Around 55% of small and mid-sized companies focus on this type because it reduces manufacturing complexity. Approximately 50% of contract manufacturers use standard fermentation techniques for these proteins, improving efficiency. Demand is supported by about 47% adoption in therapeutic areas such as growth hormones and insulin-based treatments.

Recombinant Non-glycosylated Proteins Market Size was USD 14.39 Billion in 2025, holding around 42% share of the total market and expected to grow at a CAGR of 31.04% driven by increased outsourcing and simplified production methods.

Recombinant Glycosylated Proteins

Recombinant glycosylated proteins represent nearly 58% of the Biosimilar Contract Manufacturing Market due to their wide use in complex biologics like monoclonal antibodies. Around 63% of large pharmaceutical companies prefer this type due to higher therapeutic effectiveness. Approximately 57% of manufacturing facilities are designed for glycosylated protein production due to increasing demand. These proteins are used in nearly 65% of oncology and autoimmune treatments, driving strong market demand.

Recombinant Glycosylated Proteins Market Size was USD 14.39 Billion in 2025, accounting for about 58% share of the market and expected to grow at a CAGR of 31.04% supported by rising biologic drug demand.

By Application

Oncology

Oncology accounts for nearly 35% of the Biosimilar Contract Manufacturing Market due to high demand for cancer treatment. Around 62% of biosimilars in development are focused on oncology drugs. Contract manufacturing supports nearly 68% of oncology biosimilar production due to complex processes. Increasing cancer cases and treatment demand drive about 60% of production expansion in this segment.

Oncology Market Size was USD 14.39 Billion in 2025, holding about 35% share and expected to grow at a CAGR of 31.04% due to strong demand for cancer therapies.

Blood Disorders

Blood disorder applications contribute around 18% of the Biosimilar Contract Manufacturing Market. Nearly 52% of biosimilars in this segment focus on anemia and hemophilia treatments. About 49% of manufacturers prioritize this area due to stable demand. Increasing awareness and treatment accessibility support about 45% growth in production demand.

Blood Disorders Market Size was USD 14.39 Billion in 2025, accounting for nearly 18% share and expected to grow at a CAGR of 31.04% driven by rising treatment needs.

Growth Hormonal Deficiency

Growth hormonal deficiency holds approximately 12% share in the Biosimilar Contract Manufacturing Market. Around 46% of pediatric treatment programs depend on biosimilars. Nearly 50% of manufacturers focus on this segment due to consistent demand. Increased diagnosis rates contribute to about 44% growth in production.

Growth Hormonal Deficiency Market Size was USD 14.39 Billion in 2025, representing about 12% share and expected to grow at a CAGR of 31.04%.

Chronic & Autoimmune Disorders

Chronic and autoimmune disorders contribute nearly 20% of the Biosimilar Contract Manufacturing Market. Around 58% of biologics used in autoimmune treatments are biosimilars. Approximately 55% of contract manufacturers support production for this segment due to long-term treatment needs. Rising disease prevalence supports nearly 53% increase in demand.

Chronic & Autoimmune Disorders Market Size was USD 14.39 Billion in 2025, holding about 20% share and expected to grow at a CAGR of 31.04%.

Rheumatoid Arthritis

Rheumatoid arthritis represents around 10% of the Biosimilar Contract Manufacturing Market. Nearly 54% of treatment plans include biosimilars. About 48% of manufacturers support this segment due to consistent patient demand. Improved treatment access drives about 46% production growth.

Rheumatoid Arthritis Market Size was USD 14.39 Billion in 2025, accounting for around 10% share and expected to grow at a CAGR of 31.04%.

Others

Other applications contribute nearly 5% of the Biosimilar Contract Manufacturing Market. Around 40% of niche therapies use biosimilars. Approximately 38% of contract manufacturers support these applications. Demand growth of about 35% is driven by specialized treatment needs.

Others Market Size was USD 14.39 Billion in 2025, holding about 5% share and expected to grow at a CAGR of 31.04%.

Biosimilar Contract Manufacturing Market Regional Outlook

The Biosimilar Contract Manufacturing Market shows strong global expansion supported by increasing outsourcing and biologics demand. The market size reached USD 14.39 Billion in 2025 and is projected to grow to USD 18.85 Billion in 2026 and further expand to USD 214.8 Billion by 2035, with a growth rate of 31.04%. Around 65% of pharmaceutical companies depend on contract manufacturing across regions, while nearly 58% of biologics production is outsourced globally. Regional distribution highlights that North America holds 35% share, Europe accounts for 30%, Asia-Pacific captures 25%, and Middle East & Africa contributes 10%, together making 100% of the global market. Each region shows growth driven by healthcare demand, cost efficiency, and advanced manufacturing capabilities.

North America

North America leads the Biosimilar Contract Manufacturing Market with a 35% share driven by advanced healthcare systems and strong outsourcing trends. Around 70% of pharmaceutical companies in this region rely on contract manufacturers for biosimilar production. Nearly 65% of biologics development activities are supported by third-party manufacturing services. About 60% of facilities are equipped with advanced automation systems, improving production efficiency. Investment in research contributes to approximately 58% innovation in biologics. In addition, around 62% of biosimilar demand is driven by increasing chronic disease cases and treatment needs.

North America Market Size was USD 6.60 Billion in 2026, representing 35% of the global market and expected to grow at a CAGR of 31.04% driven by strong outsourcing demand and advanced production infrastructure.

Europe

Europe holds 30% share in the Biosimilar Contract Manufacturing Market supported by favorable regulatory frameworks and high biosimilar acceptance. Around 68% of healthcare providers prefer biosimilars due to cost advantages. Nearly 60% of pharmaceutical companies outsource manufacturing activities to improve efficiency. About 55% of regulatory approvals in the region support biosimilar growth. Approximately 52% of manufacturers are expanding production capacities to meet demand. Strong public healthcare systems contribute to nearly 57% adoption of biosimilars across treatment areas.

Europe Market Size was USD 5.66 Billion in 2026, accounting for 30% share of the global market and expected to grow at a CAGR of 31.04% supported by regulatory support and rising adoption.

Asia-Pacific

Asia-Pacific represents 25% share in the Biosimilar Contract Manufacturing Market driven by cost-effective production and expanding pharmaceutical industries. Around 72% of manufacturers offer competitive pricing advantages in this region. Nearly 65% of global outsourcing demand is shifting toward Asia-Pacific due to lower operational costs. About 60% of production facilities are expanding capacity to meet rising demand. Government initiatives support approximately 58% growth in biosimilar manufacturing. Increasing healthcare access contributes to nearly 55% demand growth in this region.

Asia-Pacific Market Size was USD 4.71 Billion in 2026, representing 25% share of the global market and expected to grow at a CAGR of 31.04% driven by cost advantages and production expansion.

Middle East & Africa

Middle East & Africa accounts for 10% share in the Biosimilar Contract Manufacturing Market with steady growth driven by healthcare investments. Around 50% of governments in this region are focusing on improving biologics access. Nearly 48% of pharmaceutical companies are expanding operations in emerging markets within this region. About 45% of demand growth is supported by increasing awareness of biosimilars. Infrastructure development contributes to nearly 42% expansion in manufacturing capabilities. Rising patient population and treatment accessibility drive about 40% increase in biosimilar usage across the region.

Middle East & Africa Market Size was USD 1.88 Billion in 2026, accounting for 10% share of the global market and expected to grow at a CAGR of 31.04% supported by rising healthcare investments and demand.

List of Key Biosimilar Contract Manufacturing Market Companies Profiled

Investment Analysis and Opportunities

The Biosimilar Contract Manufacturing Market offers strong investment opportunities as demand for biologics increases. Around 64% of investors focus on expanding manufacturing facilities to meet growing needs. Nearly 58% of companies invest in advanced technologies such as single-use systems and automation. Strategic partnerships account for about 55% of investment activities, improving production efficiency. Approximately 52% of firms are entering emerging markets to reduce costs and expand reach. Capacity expansion projects contribute to nearly 60% of total investments. In addition, about 48% of funding is directed toward research and development to improve biosimilar quality and production speed. These factors create a favorable environment for long-term growth and innovation.

New Products Development

New product development plays a key role in the Biosimilar Contract Manufacturing Market. Around 62% of companies are focusing on developing monoclonal antibody biosimilars. Nearly 57% of manufacturers are introducing advanced formulations to improve treatment outcomes. Approximately 53% of research activities are focused on improving stability and shelf life. About 49% of firms are investing in next-generation biologics to meet future demand. Innovation in drug delivery systems contributes to nearly 45% of product development efforts. Additionally, around 50% of companies are working on faster production methods to reduce time-to-market. These developments support continuous growth and competitiveness in the market.

Developments

• Capacity Expansion Initiatives: Around 60% of major manufacturers expanded production facilities to meet rising biosimilar demand, improving efficiency by nearly 45% and increasing global supply capabilities.
• Technology Integration: Nearly 55% of companies adopted advanced automation and digital tools, enhancing production accuracy by about 40% and reducing operational errors significantly.
• Strategic Partnerships: Approximately 58% of firms entered collaborations with pharmaceutical companies, improving production output by nearly 50% and strengthening global presence.
• Focus on Emerging Markets: Around 52% of manufacturers expanded operations in developing regions, increasing accessibility by about 48% and reducing production costs effectively.
• Process Optimization: Nearly 50% of companies improved manufacturing processes, leading to about 42% increase in efficiency and better quality control standards.

Report Coverage

The Biosimilar Contract Manufacturing Market report provides detailed analysis of key factors influencing growth. Strength analysis shows that around 68% of companies benefit from outsourcing due to cost efficiency and scalability. Weakness analysis highlights that nearly 55% of manufacturers face challenges related to complex production and regulatory requirements. Opportunity analysis indicates that about 62% of growth potential lies in emerging markets and advanced biologics development. Threat analysis reveals that approximately 50% of companies face competition due to increasing number of contract manufacturers.

The report also covers segmentation insights, where around 60% of demand is driven by protein-based biosimilars. Regional analysis shows that nearly 35% of market activity is concentrated in developed regions, while 25% is shifting toward cost-effective regions. Technology analysis indicates that about 58% of manufacturers are adopting advanced production systems. In addition, around 53% of companies are investing in research and development to stay competitive. The report provides a clear view of market structure, competitive landscape, and growth opportunities, helping stakeholders understand key trends and future directions.

Biosimilar Contract Manufacturing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 14.39 Billion in 2026
Market Size Value By	USD 214.8 Billion by 2035
Growth Rate	CAGR of 31.04% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Recombinant Non-glycosylated Proteins Recombinant Glycosylated Proteins By Application : Oncology Blood Disorders Growth Hormonal Deficiency Chronic & Autoimmune Disorders Rheumatoid Arthritis Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Frequently Asked Questions

• What value is the Biosimilar Contract Manufacturing Market expected to touch by 2035?

  The global Biosimilar Contract Manufacturing Market is expected to reach USD 214.8 Billion by 2035.

• What CAGR is the Biosimilar Contract Manufacturing Market expected to exhibit by 2035?

  The Biosimilar Contract Manufacturing Market is expected to exhibit a CAGR of 31.04% by 2035.

• Who are the top players in the Biosimilar Contract Manufacturing Market?

  Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., Biocon, IQVIA Inc., AGC Biologics, Samsung Biologics, WuXi Biologics, Element Materials Technology, Rentschler Biopharma SE, Avid Bioservices, Inc., Alcami Corporation, Inc., Fujifilm Kyowa Kirin Biologics Co., Ltd., Thermo Fisher Scientific Inc., Almac Group,

• What was the value of the Biosimilar Contract Manufacturing Market in 2025?

  In 2025, the Biosimilar Contract Manufacturing Market value stood at USD 14.39 Billion.